Dominguez Abel Casso, Bittl John A, El-Hayek Georges, Contreras Elizabeth, Tamis-Holland Jacqueline E
Mount Sinai Saint Luke's-Roosevelt Hospital, New York, New York.
Ocala Heart Institute, Munroe Regional Medical Center, Ocala, Florida.
Catheter Cardiovasc Interv. 2016 Jun;87(7):1203-10. doi: 10.1002/ccd.26352. Epub 2015 Dec 23.
Evaluate the impact of aspiration thrombectomy (AT) during primary coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI) on clinical outcomes.
AT during PCI for STEMI may improve microvascular reperfusion, but its impact on clinical outcomes has remained controversial.
We searched Pubmed, EMBASE, Medline, Scopus, CENTRAL, andClinicalTrials.gov databases on March 31, 2015 for randomized controlled trials that evaluated the use of AT with PCI compared with PCI alone for STEMI. The primary end point was all-cause mortality. Secondary end points included major adverse cardiac events (MACE, consisting of death, myocardial infarction, and target-vessel revascularization), recurrent myocardial infarction (MI), target-vessel revascularization (TVR), stent thrombosis and stroke.
Eighteen randomized controlled trials (n = 21,501) fulfilled the inclusion criteria. A total of 10,544 patients were treated with AT and PCI, compared to 10,957 control patients. The use of AT was not associated with a significant decrease in all-cause mortality (RR 0.88; 95% CI 0.78-1.01; P = 0.07), MACE (RR 0.93; 95% CI 0.86-1.00; P = 0.06), recurrent MI (RR 0.97: 95% CI 0.81-1.17; P = 0.77), TVR (RR 0.93; 95% CI 0.82-1.05; P = 0.23), stent thrombosis (RR 0.84; 95% CI 0.66-1.07; P = 0.17), or stroke (RR 1.35; 95% CI 0.86-2.11; P = 0.19).
Using the totality of evidence available through 2015, this meta-analysis failed to show that the routine use of aspiration thrombectomy in patients with ST-elevation myocardial infarction significantly reduces all-cause mortality, MACE, recurrent MI, TVR, or stent thrombosis. The role of aspiration thrombectomy in selected patients with angiographic evidence of large thrombus burden requires further clinical investigation. © 2015 Wiley Periodicals, Inc.
评估在ST段抬高型心肌梗死(STEMI)的直接冠状动脉介入治疗(PCI)中,应用抽吸血栓切除术(AT)对临床结局的影响。
STEMI患者PCI术中应用AT可能改善微血管再灌注,但其对临床结局的影响仍存在争议。
2015年3月31日,我们检索了PubMed、EMBASE、Medline、Scopus、CENTRAL和ClinicalTrials.gov数据库,以查找评估STEMI患者应用AT联合PCI与单纯PCI相比的随机对照试验。主要终点为全因死亡率。次要终点包括主要不良心脏事件(MACE,包括死亡、心肌梗死和靶血管血运重建)、再发心肌梗死(MI)、靶血管血运重建(TVR)、支架血栓形成和卒中。
18项随机对照试验(n = 21,501)符合纳入标准。共10,544例患者接受了AT联合PCI治疗,10,957例为对照患者。应用AT与全因死亡率(RR 0.88;95%CI 0.78 - 1.01;P = 0.07)、MACE(RR 0.93;95%CI 0.86 - 1.00;P = 0.06)、再发MI(RR 0.97:95%CI 0.81 - 1.17;P = 0.77)、TVR(RR 0.93;95%CI 0.82 - 1.05;P = 0.23)、支架血栓形成(RR 0.84;95%CI 0.66 - 1.07;P = 0.17)或卒中(RR 1.35;95%CI 0.86 - 2.11;P = 0.19)的显著降低无关。
基于2015年可得的全部证据,这项荟萃分析未能表明ST段抬高型心肌梗死患者常规应用抽吸血栓切除术能显著降低全因死亡率、MACE、再发MI、TVR或支架血栓形成。抽吸血栓切除术在有血管造影证据显示血栓负荷大的特定患者中的作用需要进一步临床研究。© 2015威利期刊公司